[Corrections] Correction to Lancet Oncol 2018; 19: 580–81

Grob JJ. Is there any interest in a new BRAF–MEK inhibitor combination in melanoma? Lancet Oncol 2018; 19: 580–81—In the title of this Comment, "BRAF-MEK inhibitor" was spelt incorrectly, and in the fourth paragraph one instance of the drug "encorafenib" was spelt incorrectly and the dose of encorafenib should have been "300 mg". These corrections have been made to the online version as of April 25, 2018, and the printed Comment is correct.

https://ift.tt/2KbXWkG